WO1996018293A1 - Organ transplant solutions and method for transplanting an organ - Google Patents
Organ transplant solutions and method for transplanting an organ Download PDFInfo
- Publication number
- WO1996018293A1 WO1996018293A1 PCT/US1995/016065 US9516065W WO9618293A1 WO 1996018293 A1 WO1996018293 A1 WO 1996018293A1 US 9516065 W US9516065 W US 9516065W WO 9618293 A1 WO9618293 A1 WO 9618293A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amiloride
- solution
- organ
- containing compound
- heart
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
Definitions
- the present invention relates to cardioplegic solutions, to organ preservation solutions, and to methods for transplanting organs. More particularly, this invention relates to cardioplegic solutions for arresting an organ for transplantation, to preservation solutions for perfusing and storing an organ while awaiting implantation, and to methods for using the cardioplegic and preserving solutions during transplantation of an organ.
- organ transplantation including heart transplantation
- a significant factor limiting the clinical application of organ transplantation is the deviation of viability of the organ after removal from the donor.
- the two most frequently used methods for heart transplantation are simple hypothermic storage and continuous pulsatile perfusion.
- simple hypothermic storage the heart is arrested with a cardioplegic solution, then removed from the donor and cooled rapidly. This is usually achieved by a combination of cooling and a short period of perfusion to drop the heart temperature as quickly as possible to a temperature between 0°C. and 4°C. where it may be held up to about 6 hours.
- cold storage enables organs to be transplanted, the time during which the organ is viable is short. Cold storage decreases the rate at which intracellular enzymes, essential cellular components necessary for organ viability, degrade but does not stop metabolism.
- the second method of organ preservation which has undergone extensive investigation, continuous pulsatile perfusion, includes the following steps: (1) pulsatile flow, (2) hypothermia, (3) membrane oxygenation, and (4) a perfusate containing both albumin and lipids.
- compositions of numerous cardioplegic and preservation solutions have been extensively studied.
- the protective properties of three cardioplegic solutions were compared by Gali ⁇ anes et al .
- a comparison of cold preservation solutions was set forth in G. Tian et al . (1991) The Journal of Heart and Lung
- a storage solution for preserving organs which can be used at temperatures from 0°C. to 37°C. but was limited in storage time was disclosed in U.S. Patent No. 5,145,771 to Lemasters et al .
- the solution requires the use of the colloid, hydroxyethyl starch, for oncotic support against interstitial edema.
- edema is not a problem because no oxygen-derived free radicals are available to injure the organ.
- Preserving organs at between 0°C. and 4°C. results in damage to the organ during storage and upon reperfusion with a warm reperfusion solution. Damage to the organ occurs through the loss of endothelial cells due to dissolved oxygen in the reperfusion solution.
- reperfusion itself although necessary for the survival of the tissue, may initiate a series of events known as reperfusion induced injury, which, if occurring, limit the extent or rate of recovery.
- reperfusion induced injury which, if occurring, limit the extent or rate of recovery.
- modification of the nature of reperfusion is desirable to improve the recovery of the ischemic/reperfused myocardium.
- the sodium pump which normally maintains the intracellular composition high in potassium, magnesium, and phosphate and low in sodium and chloride, ceases to function due to the lack of energy, resulting in an inflow of sodium and chloride into the cells, and an outflow of potassium and to a lesser extent magnesium from the cells.
- the result of these rapid changes in Na * - H * distribution in the cell is a net gain, not merely an exchange, of intracellular ions followed by water and a profound loss of potassium and magnesium resulting in damage to the organ.
- Yet another object of the present invention is to provide a method of transplanting organs in which storage of the organ may be carried out at room temperature for up to at least 24 hours without significant damage to the organ.
- cardioplegic solutions and preserving solutions for use in the transplantation of organs, and to methods for transplanting organs using the solution in combination with cardioplegic solutions, which methods increase storage times and lessen injury to the organ.
- the cardioplegic solution includes a balanced isotonic solution including sodium, potassium, calcium and magnesium ions and bicarbonate in a physiologically acceptable amount, at least 0.5 ⁇ M, preferably from about 1.0 ⁇ M to about 5.0 ⁇ M, and most prefereably 1.0 ⁇ M to 3.0 ⁇ M of an amiloride-containing compound, and water sufficient to make a liter of solution.
- the cardioplegic solution also preferably contains glucose to enhance organ preservation, adenosine to prevent fibrillation of the organ prior to removal from the donor, and EDTA as a chelating agent.
- the cardioplegic solution contains heparin and at least one antioxidant.
- the preservation solution while similar to the cardioplegic solution in starting composition in that it is based on a balanced isotonic solution including sodium, potassium, calcium, magnesium ions and bicarbonate in a physiologically acceptable amount also includes from 1.0 ⁇ M to about 5.0 ⁇ M of an amiloride-containing compound.
- the preservation solution preferably includes at least one antioxidant, such as, dimethyl thiourea (DMTU) , catalase as a hydrogen peroxide scavenger and apoferritin to decrease iron content within the preservation solution. Since the organ has been arrested by the cardioplegic solution, the preservation solution includes less adenosine and heparin is not normally needed. In addition, the preservation solutions optionally may include hormones, such as insulin and prostaglandin and antibiotics.
- DMTU dimethyl thiourea
- catalase as a hydrogen peroxide scavenger
- apoferritin to decrease iron content within the preservation solution. Since the organ has been arrested by the cardioplegic solution, the preservation solution includes less adenosine and heparin is not normally needed.
- the preservation solutions optionally may include hormones, such as insulin and prostaglandin and antibiotics.
- amiloride-containing compound may be amiloride itself, or amiloride analogs, such as hexamethylene amiloride (HMA) , dimethyl amiloride (DMA) , ethyl isopropyl amiloride (EIPA) , or methyl PC17US95/16065
- HMA hexamethylene amiloride
- DMA dimethyl amiloride
- EIPA ethyl isopropyl amiloride
- PC17US95/16065 methyl PC17US95/16065
- MIA isobutyl amiloride
- the invention also provides a method for transplanting an organ which includes steps for arresting and removing the organ from the donor, and for preserving and storing the organ intended for implantation.
- the method of the invention includes arresting the organ to be donated with a cardioplegic solution.
- the organ is removed and connected to a perfusion apparatus where it is maintained at a temperature between about 0°C. to about 37°C, preferably from about 15°C. to about 25°C. while perfusing with the preservation solution.
- the novel features of the present invention include storing the organ at warm temperatures, i.e., up to about room temperature, while perfusing the organ.
- the present invention is directed to new cardioplegic solutions for arresting an organ intended for transplantation and to new preservation solutions for storing and perfusing organs intended for implantation in a patient requiring such implant.
- Suitable organs on which the solutions of this invention may be used include, for example, heart, liver, kidney and pancreas.
- the individual components of the present invention are all nontoxic and have been found to be stable during storage . While some of the components of the present invention are similar to those of other known cardioplegic and preservation solutions, it has surprisingly been found that the addition of amiloride or an amiloride-containing compound to a balanced isotonic solution including sodium, potassium, calcium, magnesium, and bicarbonate ions in a physiologically acceptable amount to form a cardioplegic solution and its use with the preservation solution of the present invention allows organs to be preserved at room temperature for at least 24 hours without significant damage to the organ.
- Both the cardioplegic solutions and the preservation solutions of the present invention are based on a balanced isotonic solution including sodium, potassium, calcium and magnesium ions as well as glucose and sodium bicarbonate in a physiologically acceptable amount.
- Certain of these types of solutions are well known, such as the one described below, known as Krebs-Henseleit-bicarbonate solution, which has the following composition:
- the cardioplegic Solution is made by starting with the balanced isotonic solution described above.
- the amount of potassium chloride in the cardioplegic solution is preferably from about 20 mM to about 30 mM.
- an amiloride-containing compound in an amount of at least 0.5 ⁇ M, preferably from about 1.0 ⁇ M to about 5.0 ⁇ M, and most preferably from 1.0 ⁇ M to 3.0 ⁇ M.
- amiloride-containing compound it is meant to include amiloride and amiloride analogs.
- amiloride designated chemically as 3, 5-diamino-6- chlor-N- (diaminomethylene) pyrazinecarboxamide monohydrochloride has been found to inhibit the ⁇ a * - H * exchange.
- amiloride-containing compounds or analogues which may be used in the cardioplegic solution include, for example, hexamethylene amiloride (HMA) designated chemically as 5- (N, N-hexamethylene) - amiloride, dimethyl amiloride (DMA) designated 5 - (N, N- dimethyl) -amiloride, ethyl isopropyl amiloride (EIPA) , designated 5- (N-ethyl -N-isopropyl) -amiloride, and methyl isobutyl amiloride (MIA) , designated 5- (N- methyl -N-isobutyl) -amiloride.
- HMA hexamethylene amiloride
- DMA dimethyl amiloride
- EIPA
- the cardioplegic solution needs to prevent fibrillation of the organ in a relatively short period of time, e.g., 2 minutes to 5 minutes or less.
- adenosine is added to the solution in an amount from about 5 ⁇ M to about 15 ⁇ M per liter, preferably about 10 ⁇ M per liter.
- Adenosine rapidly arrests the heart (within seconds) , improves the preservation properties and increases the glucose uptake.
- the cardioplegic solution also preferably includes ethylene diaminetetraacetic acid (EDTA) in an amount from 0.5 mM to about 1.5 mM as a chelating agent.
- EDTA ethylene diaminetetraacetic acid
- the solution also may optionally contain other ingredients, such as at least one antioxidant, for example, catalase, in an amount effective to inhibit the generation of oxygen-derived free radicals via hydrogen peroxide.
- Heparin is used in carrying out the method of this invention, and may be included either directly in the cardioplegic solution or it may be administered to the donor organ separately. The addition of heparin in an amount of from about 500 units to about 1500 units, preferably 1000 units is required to prevent blood clots from forming within the coronary arteries during cardioplegic arrest and excision prior to organ storage and implantation.
- the preservation solution is designed to '• prevent various mechanisms which cause injury to the organ and thus must be a composition that (1) prevents or restricts intracellular acidosis, (2) prevents the expansion of intracellular space, (3) prevents injury from oxygen-derived free radicals, especially during reperfusion, (4) enables the regeneration of high- energy phosphate compounds during reperfusion, (5) sustains appropriate metabolic requirement, and (6) prevents the rapid changes in intracellular Na + -H + -Ca ++ following reperfusion.
- the preservation solution begins with the isotonic solution, wherein the potassium concentration is maintained at preferably from 3.0 mM to about 8.0 mM.
- Magnesium chloride may be used in place of potassium chloride.
- amiloride-containing compound in an amount from about 1.0 ⁇ M to about 5.0 ⁇ M, preferably 1.5-3.0 ⁇ M.
- amiloride-containing compound it is meant to include amiloride and amiloride analogs.
- amiloride designated chemically as 3, 5-diamino-6- chlor-N- (diaminomethylene) pyrazinecarboxamide onohydrochloride has been found to inhibit the ⁇ a + - H + exchange.
- amiloride-containing compounds or analogues which may be used in the cardioplegic solution include, for example, hexamethylene amiloride (HMA) designated chemically as 5- (N, N-hexamethylene) - amiloride, dimethyl amiloride (DMA) designated 5- (N, N- dimethyl) -amiloride, ethyl isopropyl amiloride (EIPA) , designated 5- (N-ethyl -N-isopropyl) -amiloride, and methyl isobutyl amiloride (MIA) , designated 5- (N- methyl -N-isobutyl) -amiloride . (Merck Sharpe & Dohme, West Point, Pa) .
- HMA hexamethylene amiloride
- DMA dimethyl amiloride
- EIPA ethyl isopropyl amiloride
- MIA methyl isobutyl amiloride
- MIA isobutyl amiloride
- the amount of adenosine is considerably less than the amount of adenosine present in the cardioplegic solution because the organ has been previously arrested.
- the amount of adenosine in the preservation solution is normally from 0.7 ⁇ M to about 2.0 ⁇ M, preferably about 1.0 ⁇ M.
- the preservation solution also preferably includes ethylene diaminetetraacetic acid (EDTA) in an amount from 0.5 ⁇ M to about 1.5 ⁇ M as a chelating agent.
- EDTA ethylene diaminetetraacetic acid
- Suitable antioxidants include, but are not limited to, allopurinol, glutathione, beta-carotene, catalase, superoxide dismutase, dimethyl thiourea (DMTU) , diphenyl phenylene diamine (DPPD) , mannitol or cyanidanol in an amount effective to inhibit the generation of oxygen-derived free radicals.
- the antioxidants are present in an amount from 1 77M to 10 77M.
- Antibiotics may be added for transplantable organs, but is not generally added during acute studies.
- the transplantation method of the present invention is to arrest the organ using the cardioplegic solution, preserve and store the organ with the preservation solution and reperfuse with the preservation solution.
- sufficient cardioplegic solution is injected to arrest, for example the heart and prevent fibrillation.
- the surgeon then removes the organ and connects the heart to a perfusion apparatus comprising tubing and pumps .
- the preservation solution is then perfused through the heart while gassed with oxygen and carbon dioxide while it is awaiting implantation into a patient .
- a perfusion rate of 50 mL/hour at 1.0°C. has been found to be effective.
- the method of perfusing the heart can be at either a constant flow or pressure.
- the solution can be used at all temperatures ranging from 0°C. to normal body temperature, 37°C. At temperatures of from about 12°C. to about 37°C, the solution is more protective than other known preservation solutions. Unlike other storage solutions, it continues to be protective above 10°C. for at least 24 hours.
- Example 1 is provided to further illustrate the present invention and are not to be construed as limiting the invention in any manner.
- Example 1
- a liter of cardioplegic solution having the following composition was prepared.
- a liter of preservation solution having the following composition was prepared.
- the preservation solution was prepared in much the same manner as the cardioplegic solution of Example I, that is, by adding a Krebs-Heneseleit solution to a 1000 mL volumetric flask with double distilled water to make one liter while stirring. The rest of the components were added one at a time and the pH of the solution was adjusted to about 7.3 with NaOH and gassed with 95% oxygen plus 5% carbon dioxide.
- a female mongrel dog weighing about 20 kg. was anesthetized.
- An IV hydrating solution of 5.0% dextrose in 0.45% saline at 75 cc/hr was given throughout the procedure .
- the heart was exposed by a sternotomy.
- the cardioplegic solution of Example 1 was administered to arrest the heart, the heart was then excised.
- the heart was placed in ice and promptly transferred to the laboratory and placed in a perfusion apparatus at room temperature where the aorta was attached to a tube for continuous perfusion with the preserving solution of Example 2. After 2-3 minutes the heart started beating at a pulse rate of 50 beats per minute.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95943059A EP0797384A4 (en) | 1994-12-12 | 1995-12-11 | Organ transplant solutions and method for transplanting an organ |
AU44203/96A AU4420396A (en) | 1994-12-12 | 1995-12-11 | Organ transplant solutions and method for transplanting an organ |
MX9704374A MX9704374A (en) | 1994-12-12 | 1995-12-11 | Organ transplant solutions and method for transplanting an organ. |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/354,503 US5554497A (en) | 1994-12-12 | 1994-12-12 | Cardioplegic solution for arresting an organ |
US08/354,503 | 1994-12-12 | ||
US08/563,222 | 1995-11-27 | ||
US08/563,222 US5693462A (en) | 1994-12-12 | 1995-11-27 | Organ transplant solutions and method for transplanting an organ |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996018293A1 true WO1996018293A1 (en) | 1996-06-20 |
Family
ID=26998430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/016065 WO1996018293A1 (en) | 1994-12-12 | 1995-12-11 | Organ transplant solutions and method for transplanting an organ |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0797384A4 (en) |
AU (1) | AU4420396A (en) |
CA (1) | CA2207324A1 (en) |
MX (1) | MX9704374A (en) |
WO (1) | WO1996018293A1 (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999017784A1 (en) * | 1997-10-07 | 1999-04-15 | Regents Of The University Of California Corporation | Treating occlusive peripheral vascular disease and coronary disease with combinations of heparin and an adenoside a2 agonist, or with adenosine |
US5972903A (en) * | 1997-10-07 | 1999-10-26 | Regents Of The University Of California Corporation | Method for promoting angiogenesis using heparin and adenosine |
WO2002102149A1 (en) * | 2001-06-14 | 2002-12-27 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Solution for the storage and perfusion of organs awaiting transplantation |
WO2012078968A3 (en) * | 2010-12-10 | 2012-08-02 | Lifeline Scientific, Inc. | Machine perfusion with complement inhibitors |
EP2611291A1 (en) * | 2010-09-01 | 2013-07-10 | Organ Perfusion Pty Limited | Perfusion composition |
WO2014042545A1 (en) | 2012-09-14 | 2014-03-20 | Transmedium Sp. Z O.O. | Solutions for protecting, perfusing and storing organs during surgical procedures in particular transplantations |
US9055740B2 (en) | 2004-10-07 | 2015-06-16 | Transmedics, Inc. | Systems and methods for ex-vivo organ care |
US9078428B2 (en) | 2005-06-28 | 2015-07-14 | Transmedics, Inc. | Systems, methods, compositions and solutions for perfusing an organ |
US9247728B2 (en) | 2008-01-31 | 2016-02-02 | Transmedics, Inc. | Systems and methods for ex vivo lung care |
US9301519B2 (en) | 2004-10-07 | 2016-04-05 | Transmedics, Inc. | Systems and methods for ex-vivo organ care |
US9457179B2 (en) | 2007-03-20 | 2016-10-04 | Transmedics, Inc. | Systems for monitoring and applying electrical currents in an organ perfusion system |
US9756851B2 (en) | 1997-09-23 | 2017-09-12 | The Department Of Veteran Affairs | Compositions, methods and devices for maintaining an organ |
US9894894B2 (en) | 2004-10-07 | 2018-02-20 | Transmedics, Inc. | Systems and methods for ex-vivo organ care and for using lactate as an indication of donor organ status |
US10076112B2 (en) | 2014-06-02 | 2018-09-18 | Transmedic, Inc. | Ex vivo organ care system |
US10194655B2 (en) | 2015-09-09 | 2019-02-05 | Transmedics, Inc. | Aortic cannula for ex vivo organ care system |
US11856944B2 (en) | 2011-04-14 | 2024-01-02 | Transmedics, Inc. | Organ care solution for ex-vivo machine perfusion of donor lungs |
US11963526B2 (en) | 2021-07-09 | 2024-04-23 | Transmedics, Inc. | Apparatus and method for organ perfusion |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2089336A1 (en) * | 1990-09-12 | 1993-08-13 | Stephen A. Livesey | Method for processing and preserving collagen-based tissues for transplantation |
-
1995
- 1995-12-11 AU AU44203/96A patent/AU4420396A/en not_active Abandoned
- 1995-12-11 MX MX9704374A patent/MX9704374A/en unknown
- 1995-12-11 EP EP95943059A patent/EP0797384A4/en not_active Withdrawn
- 1995-12-11 CA CA 2207324 patent/CA2207324A1/en not_active Abandoned
- 1995-12-11 WO PCT/US1995/016065 patent/WO1996018293A1/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2089336A1 (en) * | 1990-09-12 | 1993-08-13 | Stephen A. Livesey | Method for processing and preserving collagen-based tissues for transplantation |
Non-Patent Citations (5)
Title |
---|
CIRCULATION RESEARCH, Volume 66, Number 4, issued April 1990, DENNIS et al., "Effects of Proton Buffering and of Amiloride Derivatives on Reperfusion Arrhythmias in Isolated Rat Hearts", pages 1156-1159. * |
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, Volume 25, issued 1993, MOFFAT et al., "Protective Effects of the Potent Na/H Exchange Inhibitor Methylisobutyl Amiloride Against Post-Ischemic Contractile Dysfunction in Rat and Guinea Pig Hearts", pages 959-971. * |
See also references of EP0797384A4 * |
THE JOURNAL OF HEART AND LUNG TRANSPLANTATION, Volume 11, Number 4, Part 1, issued July/August 1992, GALINANES et al., "Long-Term Hypothermic Storage of the Mammalian Heart for Transplantation: A Comparison of Three Cardioplegic Solutions", pages 624-635. * |
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, Volume 265, Number 3, issued 1993, PIERCE et al., "Modulation of Cardiac Performance by Amiloride and Several Selected Derivatives of Amiloride", pages 1280-1291. * |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9756851B2 (en) | 1997-09-23 | 2017-09-12 | The Department Of Veteran Affairs | Compositions, methods and devices for maintaining an organ |
US9756850B2 (en) | 1997-09-23 | 2017-09-12 | The Department Of Veteran Affairs | Compositions, methods and devices for maintaining an organ |
US9756849B2 (en) | 1997-09-23 | 2017-09-12 | The Department Of Veteran Affairs | Compositions, methods and devices for maintaining an organ |
US5972903A (en) * | 1997-10-07 | 1999-10-26 | Regents Of The University Of California Corporation | Method for promoting angiogenesis using heparin and adenosine |
US6440947B1 (en) | 1997-10-07 | 2002-08-27 | The Regents Of The University Of California | Method for treating occlusive peripheral vascular disease and coronary disease |
WO1999017784A1 (en) * | 1997-10-07 | 1999-04-15 | Regents Of The University Of California Corporation | Treating occlusive peripheral vascular disease and coronary disease with combinations of heparin and an adenoside a2 agonist, or with adenosine |
WO2002102149A1 (en) * | 2001-06-14 | 2002-12-27 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Solution for the storage and perfusion of organs awaiting transplantation |
US7422844B2 (en) | 2001-06-14 | 2008-09-09 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Solution for the storage and perfusion of organs awaiting transplantation |
US7989158B2 (en) | 2001-06-14 | 2011-08-02 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Solution containing carnitine for the storage and perfusion of organs awaiting transplantation |
US8007993B2 (en) | 2001-06-14 | 2011-08-30 | Sigma—Tau Industrie Farmaceutiche Riunite, S.p.A. | Method for storage and perfusion of organs using a solution comprising L-carnitine and isovaleryl L-carnitine |
US10736314B2 (en) | 2004-10-07 | 2020-08-11 | Transmedics, Inc. | Systems and methods for ex-vivo organ care and for using lactate as an indication of donor organ status |
US11570985B2 (en) | 2004-10-07 | 2023-02-07 | Transmedics, Inc. | Systems and methods for ex-vivo organ care and for using lactate as an indication of donor organ status |
US11723357B2 (en) | 2004-10-07 | 2023-08-15 | Transmedics, Inc. | Systems and methods for ex-vivo organ care |
US9215867B2 (en) | 2004-10-07 | 2015-12-22 | Transmedics, Inc. | Systems and methods for ex-vivo organ care |
US9055740B2 (en) | 2004-10-07 | 2015-06-16 | Transmedics, Inc. | Systems and methods for ex-vivo organ care |
US9301519B2 (en) | 2004-10-07 | 2016-04-05 | Transmedics, Inc. | Systems and methods for ex-vivo organ care |
US11191263B2 (en) | 2004-10-07 | 2021-12-07 | Transmedics, Inc. | Systems and methods for ex-vivo organ care |
US10321676B2 (en) | 2004-10-07 | 2019-06-18 | Transmedics, Inc. | System and methods for ex-vivo organ care and for using lactate as an indication of donor organ status |
US10314303B2 (en) | 2004-10-07 | 2019-06-11 | Transmedics, Inc. | Systems and methods for ex-vivo organ care |
US9894894B2 (en) | 2004-10-07 | 2018-02-20 | Transmedics, Inc. | Systems and methods for ex-vivo organ care and for using lactate as an indication of donor organ status |
US10039276B2 (en) | 2005-06-28 | 2018-08-07 | Transmedics, Inc. | Systems, methods, compositions and solutions for perfusing an organ |
US9078428B2 (en) | 2005-06-28 | 2015-07-14 | Transmedics, Inc. | Systems, methods, compositions and solutions for perfusing an organ |
US11844345B2 (en) | 2005-06-28 | 2023-12-19 | Transmedics, Inc. | Systems, methods, compositions and solutions for perfusing an organ |
US10327443B2 (en) | 2007-03-20 | 2019-06-25 | Transmedics, Inc. | Systems for monitoring and applying electrical currents in an organ perfusion system |
US11917991B2 (en) | 2007-03-20 | 2024-03-05 | Transmedics, Inc. | Systems for monitoring and applying electrical currents in an organ perfusion system |
US9457179B2 (en) | 2007-03-20 | 2016-10-04 | Transmedics, Inc. | Systems for monitoring and applying electrical currents in an organ perfusion system |
US9814230B2 (en) | 2008-01-31 | 2017-11-14 | Transmedics, Inc. | Systems and methods for ex vivo lung care |
US9516875B2 (en) | 2008-01-31 | 2016-12-13 | Transmedics, Inc. | Systems and methods for ex vivo lung care |
US9462802B2 (en) | 2008-01-31 | 2016-10-11 | Transmedics, Inc. | Systems and methods for ex vivo lung care |
US10750738B2 (en) | 2008-01-31 | 2020-08-25 | Transmedics, Inc. | Systems and methods for ex vivo lung care |
US9247728B2 (en) | 2008-01-31 | 2016-02-02 | Transmedics, Inc. | Systems and methods for ex vivo lung care |
EP2611291A4 (en) * | 2010-09-01 | 2014-05-14 | Perfusion Fluid Technologies Inc | Perfusion composition |
EP2611291A1 (en) * | 2010-09-01 | 2013-07-10 | Organ Perfusion Pty Limited | Perfusion composition |
WO2012078968A3 (en) * | 2010-12-10 | 2012-08-02 | Lifeline Scientific, Inc. | Machine perfusion with complement inhibitors |
US11856944B2 (en) | 2011-04-14 | 2024-01-02 | Transmedics, Inc. | Organ care solution for ex-vivo machine perfusion of donor lungs |
WO2014042545A1 (en) | 2012-09-14 | 2014-03-20 | Transmedium Sp. Z O.O. | Solutions for protecting, perfusing and storing organs during surgical procedures in particular transplantations |
US11154050B2 (en) | 2014-06-02 | 2021-10-26 | Transmedics, Inc. | Ex vivo organ care system |
US11903381B2 (en) | 2014-06-02 | 2024-02-20 | Transmedics, Inc. | Ex vivo organ care system |
US10076112B2 (en) | 2014-06-02 | 2018-09-18 | Transmedic, Inc. | Ex vivo organ care system |
US11944088B2 (en) | 2014-06-02 | 2024-04-02 | Transmedics, Inc. | Ex vivo organ care system |
US11122795B2 (en) | 2015-09-09 | 2021-09-21 | Transmedics, Inc. | Aortic cannula for ex vivo organ care system |
US10194655B2 (en) | 2015-09-09 | 2019-02-05 | Transmedics, Inc. | Aortic cannula for ex vivo organ care system |
US11963526B2 (en) | 2021-07-09 | 2024-04-23 | Transmedics, Inc. | Apparatus and method for organ perfusion |
Also Published As
Publication number | Publication date |
---|---|
MX9704374A (en) | 1998-02-28 |
CA2207324A1 (en) | 1996-06-20 |
EP0797384A1 (en) | 1997-10-01 |
AU4420396A (en) | 1996-07-03 |
EP0797384A4 (en) | 2000-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5693462A (en) | Organ transplant solutions and method for transplanting an organ | |
US5702881A (en) | Method and solution for organ preservation comprising retinal-derived growth factor, cyclodextrin, mucopolysaccharide and fluorocarbon | |
EP1257169B1 (en) | System for organ and tissue preservation and hypothermic blood substitution | |
US8236486B2 (en) | Flush preservation solution | |
WO1996018293A1 (en) | Organ transplant solutions and method for transplanting an organ | |
US8802361B2 (en) | Composition and method for the restoration and preservation of transplant organs procured from DCD donors | |
JPH01246201A (en) | Solution for preserving organ | |
JPH09500380A (en) | Solution for tissue preservation and bloodless surgery, and method using the same | |
MXPA97004374A (en) | Solutions for organ transplants and method to transplant an org | |
Guerraty et al. | Successful orthotopic canine heart transplantation after 24 hours of in vitro preservation | |
Jeevanandam et al. | Cardiac transplantation after prolonged graft preservation with the University of Wisconsin solution | |
WO2002049653A1 (en) | Compositions for preservation of organs and blood | |
EP2991481A1 (en) | Formulations containing poly (0-2-hydroxyethyl) starch for increasing the oxygen-content, stability and shelf life of an organ and tissue preservation solution | |
Swanson et al. | Improving function of hearts preserved for 24 hours by controlling reperfusion | |
Toledo-Pereyra et al. | Preservation of canine hearts after warm ischemia (zero to thirty minutes) and one to two days of hypothermic storage: a comparative analysis of crystalloid and colloid solutions with different osmolarity and ion composition | |
Baron et al. | Retrospective clinical comparison of Celsior solution to modified blood Wallwork solution in lung transplantation for cystic fibrosis | |
EP3209128A1 (en) | Novel composition and solution with controlled calcium ion level, and related method and use for reperfusion | |
JPH0822801B2 (en) | Solution for organ preservation | |
KR100304594B1 (en) | Composition for the Preservation of Organs and Blood Cells | |
Baumgartner | Myocardial and pulmonary protection: long-distance transport | |
Ogiwara et al. | A comparison of the University of Wisconsin solution and the modified Kawakami solution for initial flush and coronary perfusion in long-term canine heart preservation | |
Martin et al. | Protection Strategies for Heart Transplantation | |
Jablonski et al. | A new rat pancreas transplant model | |
WO1999045769A2 (en) | Preservation solution | |
JPH05271001A (en) | Initial perfusate solution for transplanting organ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2207324 Country of ref document: CA Ref country code: CA Ref document number: 2207324 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1997/004374 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995943059 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995943059 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995943059 Country of ref document: EP |